Evidence map›Paper›PMID 42124925›Full record

ArticleJAC-antimicrobial resistance2026

Clinical implications of cefoperazone-sulbactam MIC values in

Shian-Sen Shie, Ting-Shu Wu, Feng-Yee Chang, Ya-Sung Yang, Tsung-Ta Chiang, Mao-Wang Ho, Chia-Hui Chou, Po-Liang Lu, Shang-Yi Lin, Fu-Der Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shian-Sen ShieDivision of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0001-6891-5205
Ting-Shu WuDivision of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0001-6710-3432
Feng-Yee ChangDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ya-Sung YangDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Tsung-Ta ChiangDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Mao-Wang HoDivision of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Chia-Hui ChouDivision of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Po-Liang LuDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Shang-Yi LinDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Fu-Der WangDivision of Infectious Diseases, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Hung-Jen TangDepartment of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Zhi-Yuan ShiDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Yin-Ching ChuangDepartment of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Jien-Wei LiuDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cefoperazone/sulbactam (CPZ/SUL, 1:1) is used for Methods: We retrospectively analysed 122 adults with Results: Overall, 76.2% achieved favourable outcomes. Patients with MICs ≤16 mg/L had significantly higher favourable rates than those with MICs ≥32 mg/L (81.0% versus 54.5%; Conclusions: Lower CPZ/SUL MIC values were independently associated with more favourable clinical outcomes in patients with

Identifiers

PMID42124925
PMCPMC13158015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.